Bayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on its molecular signature rather than its location in the body. The EU drugs regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback